Showing 1751-1760 of 2038 results for "".
- Amgen and Horizon Therapeutics Resolve FTC Lawsuit Clearing Path to Acquisitionhttps://modernod.com/news/amgen-and-horizon-therapeutics-resolve-ftc-lawsuitclearing-path-to-acquisition/2481806/Amgen and Horizon Therapeutics announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. The order clears a path forward to closing its planned $27.8-billion takeout 
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- Oculis Announces that OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Primary Endpoints in Phase 3 OPTIMIZE Trialhttps://modernod.com/news/oculis-announces-that-ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-primary-endpoints-in-phase-3-optimize-trial/2481769/Oculis announced positive topline results from its phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical Optireach formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery. OPTI
- Oculis’ OCS-01 Eye Drops Studied in LEOPARD Trial to Treat Cystoid Macular Edemahttps://modernod.com/news/oculis-ocs-01-eye-drops-studied-in-leopard-trial-to-treat-cystoid-macular-edema/2481763/Oculis announced that the first patient has been enrolled in the investigator-initiated LEOPARD trial evaluating the potential of OCS-01 eye drops, Oculis’ high-concentration preservative-free topical Optireach formulation of dexamethasone, for the treatment of cystoid macular edema (CME).<
- FDA Approves Xdemvy, First Treatment for Demodex Blepharitishttps://modernod.com/news/fda-approves-xdemvy-first-treatment-for-demodex-blepharitis/2481743/The FDA has approved Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution 0.25%) for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause
- FDA Approves Novaliq's Cyclosporine Eye Drop Vevye for Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-approval-of-vevye-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481664/Just 3 weeks after receiving FDA approval for dry eye drug Miebo, Novaliq has received FDA approval for Vevye (cyclosporine ophthalmic solution; formerly known as CyclASol) 0.1% for the treatment of the signs and symptoms of dry eye disease. Novaliq says Vevye is the first and only
- NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem Cellshttps://modernod.com/news/nei-scientists-publish-recipe-for-making-blood-vessel-cells-from-patient-stem-cells/2481626/Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. &ldquo
- FDA Approves Bausch + Lomb and Novaliq's Miebo for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/bausch-lomb-and-novaliq-announce-fda-approval-of-miebotm-perfluorohexyloctane-ophthalmic-solution-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481625/Bausch + Lomb announced on Thursday that the FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) for the treatment of the signs and symptoms of dry eye disease (DED). The comapnies say Miebo is the first and only FDA-approved treatment fo
- Invirsa Completes Enrollment of Phase 1/2a Dry Eye Studyhttps://modernod.com/news/invirsa-completes-enrollment-of-phase-12a-dry-eye-study/2481619/Invirsa announced that its first clinical trial, a phase 1/2a study with the primary objective to determine safety and preliminary efficacy of Invirsa's topically administered eye drop formulation of INV-102, has completed enrollment. Subjects had moderate dry eye and dosing was well tol
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term